Surrozen, Inc. (SRZNW)

0,0200 -0,0021 (-9,50%) Ab 11:03AM EDT. Markt geöffnet.

Surrozen, Inc.

171 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
650 489 9000
https://www.surrozen.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 42

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Craig C. Parker M.B.A.	CEO, President & Director	825,32k	N/A	1962
Mr. Charles Williams	CFO, COO & Corporate Secretary	611,03k	N/A	1980
Dr. Li Yang Ph.D.	Executive Vice President of Research	535,46k	N/A	1969
Dr. K. Christopher Garcia Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Roeland Nusse Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1950
Dr. Calvin Kuo M.D., Ph.D.	Co-Founder & Member of Scientific Advisor	N/A	N/A	N/A
Esther Jhun	Controller	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Corporate Governance

Surrozen, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.